ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

The licensing agreement, announced Monday, gives Vanda (NASDAQ: VNDA) global and exclusive rights to market imsidolimab. San Diego-based AnaptysBio Inc. (NASDAQ: ANAB) handled the drug's research ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab ...

The deal grants Vanda global rights to imsidolimab, which has shown positive results in two Phase 3 trials for Generalized Pustular Psoriasis or GPP, a rare and life-threatening skin condition.

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization of imsidolimab, which has successfully completed two ...

After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the skin disorder psoriasis.

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys ...

This forecast includes Fanapt, HETLIOZ, and PONVORY but excludes potential contributions from tradipitant or imsidolimab. For 2030, Vanda targets psychiatry portfolio revenues exceeding $750 ...

The company is also advancing its other candidates, including ANB033 and ANB101, and has entered into a global licensing agreement with Vanda Pharmaceuticals to develop imsidolimab, an IL-36R ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever ...

1 Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development ...